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Background: Chronic rhinosinusitis is common in cystic ﬁbrosis (CF), as CFTR defects equally affect the airway and sinonasal mucosa. However,
therapeutic strategies for CF-associated chronic rhinosinusitis lag behind current approaches for pulmonary disease.
Objective: To assess the tolerability and efﬁcacy of a nasal spray formulation containing 0.2% sodium hyaluronate and 3% tobramycin compared
to a control formulation containing 0.2% sodium hyaluronate alone in the treatment of bacterial rhinosinusitis in patients with CF.
Methods: In a double-blind controlled study, 27 patients with an established diagnosis of CF and a documented nasal infection with Pseudomonas
aeruginosa and/or Staphylococcus aureus [22 males (81%), median age of 15 years (range 5–26 yrs)], were randomized to receive the nasal spray
formulation containing hyaluronate and tobramycin (N = 14) or hyaluronate alone (N = 13) for 14 days. Efﬁcacy and local tolerability of the
treatments were assessed by ear, nose and throat (ENT) examination and related symptoms.
Results: The formulation containing hyaluronate and tobramycin was more effective than hyaluronate alone in improving the status of the nasal
mucosa, in reducing the mucopurulent secretion at the level of the osteomeatal complex and in improving ENT symptoms (hyposmia/anosmia and
headache/facial pain). The treatment was well tolerated without relevant side effects.
Conclusions: The present study suggests that the combination therapy with hyaluronate plus tobramycin was more effective than hyaluronate alone
in the treatment of bacterial rhinosinusitis in CF. Trial registration number: EudraCT 2007-003628-39.
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f.V. Aage groups [1,2], with classic and atypical form of the disease
[3]. It is associated with a wide spectrum of clinical symptoms
(including nasal obstruction, impaired olfactive function and
facial pain) that have a significant impact on quality of life [4].
Recently, the influence of the upper airways on the general
health of CF patients has been the object of investigation to
verify the hypothesis that sinonasal involvement may function
as a reservoir for pulmonary infection. Several studies have
documented concordance between microorganisms isolated in
the upper and lower airways, supporting the unified airwayll rights reserved.
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may precede spread to the lower airways [5–8].
In a group of 16 CF patients who underwent endonasal
endoscopic sinus surgery, a significant association was found
between bronchoalveolar lavages and sinus cultures [5].
More recently, a cross-sectional study in adult CF patients
also comparing upper and lower cultures has shown one or
more concordant microorganism in 50% of the patients [8].
Pseudomonas aeruginosawas frequently cultured from upper
airways and this also occurred after eradication therapy.
Treatment strategies for CF-associated chronic rhinosinusitis
vary but usually include a combination of endoscopic sinus
surgery, systemic and topical antibiotics/steroids and nasal
irrigations [9]. In consideration of the unified airway concept,
other therapeutic interventions currently used for pulmonary
disease provide potential benefits.
Hyaluronic acid (HA) has been shown to exert beneficial
effects in experimental models of chronic respiratory diseases
[10]. Due to its water-retaining properties, it humidifies and
protects the respiratory airways against injury and is also
provided of anti-inflammatory properties [11]. More recently,
nebulized HA has been shown to be effective in controlling
inflammation in vivo in mice CF airways and in vitro in human
airway epithelial cells, thus providing the proof of concept for
its use as a potential anti-inflammatory drug in CF therapy [12].
HA inhalation has also been shown to be effective and safe in
CF patients with lung disease [13]. However, the inhalation of
HA alone does not decrease bacterial load in these patients.
Therefore, a nasal spray formulation of HA plus tobramycin
was developed to provide the benefits of HA together with the
bacteriostatic and bactericidal (at high concentration) effects of
tobramycin.
In this study, we compared the efficacy and tolerability of
this new formulation with a nasal spray formulation containing
HA alone, in the treatment of bacterial rhinosinusitis in patients
with CF.
2. Materials and methods
2.1. Study design
We carried out a randomized, double-blind controlled parallel-
group pilot study aimed to test the tolerability and efficacy of
a 2-week treatment of a nasal spray formulation containing
0.2% sodium hyaluronate and 3% tobramycin compared to
a control formulation containing 0.2% sodium hyaluronate
alone in CF-associated bacterial rhinosinusitis. The study was
carried out at the CF Centre, Fondazione IRCSS, Ca' Granda
Ospedale Maggiore Policlinico of Milan in compliance with
the Declaration of Helsinki and the International Conference
on Harmonisation (ICH) guidelines for Good Clinical Practice.
The institutional ethics committee approved the study, and all
patients or their guardians provided written informed consent
prior to undergoing any study procedures. The trial registration
number is EudraCT 2007-003628-39.
Patients older than 6 years with an established diagnosis
of CF (sweat chloride N60 mEq/L and/or presence of two CFcausing mutations), symptoms of rhinosinusitis and a forced
expiratory volume in one second (FEV 1) of at least 30% of the
predicted value were considered for the enrolment. Exclusion
criteria were a history of hypersensitivity to aminoglycosides, a
negative sinus culture for both P. aeruginosa and Staphylococcus
aureus, pregnancy or breastfeeding and the use of systemic
antibiotics within 30 days before enrolment in the study.
Patients colonized by Burkholderia cepacia were also excluded
because of the multidrug resistance of the bacterium. Finally, in
consideration of the nasal route of administration, patients with
deviation of nasal septum totally obstructing one nasal cavity or
suffering from allergic rhinitis or sinonasal polyposis, those with
ongoing or recurrent epistaxis or with a history of endoscopic
sinus surgery in the 6 months preceding enrolment were excluded
from the study.
During the study period, patients were allowed to take their
usual treatments or to take drugs for any concomitant diseases.
However, systemic antibiotic treatment or local nasal treatments
with anti-inflammatory drugs were not allowed for the duration
of the study.
In all eligible patients, swab cultures obtained from
osteomeatal complex were taken under endoscopic control for
the identification of pathogens (P. aeruginosa and/or S. aureus
bacteria). We considered the middle meatus representative for
the upper airways as a concordance of cultures obtained by
middle meatal swab with maxillary sinus aspirate has been
confirmed by a meta-analysis [14]. The nasal swabs were
placed into 1 mL of 0.9% sodium chloride for processing. After
20 min, the samples were vortexed and 0.1 mL was cultured on
different agar plates to detect Gram-positive and Gram-negative
bacteria. All samples were incubated aerobically at 37 °C
and were analysed for growth of bacteria after 18 h and then
every 24 h during 7 consecutive days. Each microorganism
isolated was identified by a standardized and automated
method (Microscan System Siemens HD). A sputum culture
was also performed at the same day visit. Enrolled patients were
randomly assigned to one of the two treatment groups using a
computer generated randomization code. The test nasal spray
formulation consisted of a 10-mL aqueous solution containing
0.2% sodium hyaluronate (MW 0.3–0.5 Mda, obtained by
fermentation from Streptococcus equi bacterial strain; CPN
Spol Dolni Dobrouc 401, 561 02) and 3% tobramycin sulphate.
The control nasal spray formulation was identical in presentation
but contained only 0.2% sodium hyaluronate. The two test
products were packed in identical containers. Each patient
nebulized 100 μL of the assigned product into each nostril 3
times a day for 14 days.
The study participants, investigators and study monitors
were blind to the treatment assigned to the patients. However,
the investigator had access to a sealed envelope containing
the randomisation code of each patient to be opened in case of
a medical emergency. Data entry and data analysis were
also performed in a blind manner, i.e., before the codes were
broken.
At baseline (Visit 1, Day 1) and at the end of the study
(Visit 2, Day 14), patients underwent nasal endoscopy using the
2.2 flexible optical scope from Olympus NF XP (Olympus
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and throat (ENT) symptoms, including nasal obstruction,
mucopurulent rhinorrhea, hyposmia/anosmia, snoring, head-
ache and facial pain.
Local tolerability of the 2 formulations was assessed
through ENT examination and occurrence of new symptoms
(specifically dryness of the mucosa, bleeding and/or sneezing)
and/or worsening of already present symptoms. Treatment was
considered tolerable if the patients did not report worsening or
occurrence of ENT symptoms and if the endoscopic evaluation
did not show an alteration of the nasal mucosa.
At endoscopic evaluation, nasal mucosa was classified as
eutrophic (healthy and well hydrated), hyperaemic (flushed with
evident vascular ectasia) or dystrophic (dry, pale and atrophic). In
addition, we evaluated the presence ofmucopurulent secretions at
the level of osteomeatal complex (suggestive for infectious/
flogistic involvement of the anterior compartment of paranasal
sinuses) and of hypertrophy of turbinates (particularly the
lower, with consequent choanal obstruction and accumulation
of secretions).Table 1
Baseline characteristics of the patients.
Hyaluronate
(N = 13)
Hyaluronate +
tobramycin
(N = 14)
Gender (M/F) 10/3 12/2
Age, median (range) 15 (5–24) 16 (6–26)
Genotype
Delta F508 homozygous, n (%) 3 (23%) 3 (21%)
Delta F508 heterozygous, n (%) 4 (31%) 6 (43%)
Others, n (%) 6 (46%) 5 (36%
Pancreatic insufficiency, n (%) 7 (54%) 8 (57%)
Positive Pseudomonas aeruginosa
Sputum, n (%) 0 6 (43%)
Nasal swab, n (%) 0 4 (29%)
Positive Staphylococcus aureus
Sputum, n (%) 8 (62%) 9 (64%)
Nasal swab, n (%) 13 (100%) 12 (86%)
FEV1 (% of the predicted value),
median (range)
101 (50–120) 98 (36–127)
Symptoms
Nasal obstruction
Absent, n (%) 0 1 (7%)
Occasional, n (%) 5 (38%) 8 (57%)
Continuous, n (%) 8 (62%) 5 (36%)
Mucopurulent rhinorrhea
(subjective evaluation), n (%)
12 (92%) 12 (86%)
Hyposmia/anosmia, n (%) 8 (62%) 12 (86%)2.2. Statistical analysis
Study outcomes were as follows: changes in symptoms related
to sinonasal infection, mucosal inflammation and reduction of
bacterial load in nasal swab, expressed in colony forming unit
(CFU)/mL. Changes in ENT symptoms and in signs of mucosal
inflammation were categorized as follows: improvement (symp-
toms/signs present at baseline and absent at visit 2), worsening
(symptoms/signs absent at baseline and present at visit 2) or no
change (symptoms/signs absent at baseline and at visit 2 or
symptom present at baseline and at visit 2).
Considering that for many outcomes the category “worsening”
had an observed frequency equal to 0 and an expected frequency
less than 5 we pooled the categories “worsening” and “no
change” and performed the Fisher's exact test to verify if the
proportions of patients in the categories of the outcome are
independent of the treatment group.
As a secondary objective, we evaluated the association
between upper airways and lower airways infections in all the
screened patients. The odds of a positive sputum culture for
S. aureus or P. aeruginosa in patients with a positive and negative
sinus specimen were calculated. The odds ratios (ORs) and their
95% CIs were also computed.
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS v. 15.0) and significance
was set at α b 0.05.Snoring, n (%) 8 (62%) 9 (64%)
Headache/facial pain, n (%) 8 (62%) 12 (86%)
Endoscopic evaluation
Nasal mucosa
Eutrophic, n (%) 0 0
Hyperemic, n (%) 10 (77%) 11 (79%)
Dystrophic, n (%) 3 (23%) 3 (21%)
Mucopurulent secretion of
osteomeatal complex, n (%)
12 (92%) 13 (93%)
Hypertrophy of the left turbinate, n (%) 10 (77%) 12 (86%)
Hypertrophy of the right turbinate, n (%) 11 (85%) 13 (93%)3. Results
Fifty-nine patients with symptoms suggestive of bacterial
rhinosinusitis were screened but 32 were excluded: 20 patients
had a negative sinus culture and 12 patients (10 with positive
cultures for S. aureus and 2 for P. Aeruginosa) were not included
because of systemic antibiotic treatment within 30 days before
enrolment). Twenty-seven patients with a positive sinus swabculture (23 for S. aureus, 2 for P. aeruginosa and 2 for both
bacteria) were enrolled in the study.
The enrolled patients were randomly assigned to receive the
test formulation (N = 14) or the control formulation (N = 13)
for 14 days. The baseline characteristics of the patients are
shown in Table 1.
Patients were comparable for demographic and clinical
characteristics, with the exception of a higher proportion of
P. aeruginosa-positive cultures and a lower prevalence of
continuous nasal obstruction in patients receiving HA and
tobramycin (Table 1).
The presence of 3% tobramycin in the test formulation did
not modify the already known tolerability of the 0.2% sodium
hyaluronate control nasal formulation [15]. Both formulations
were well tolerated; none of the patients reported significant
worsening or occurrence of ENT symptoms including dryness,
bleeding and/or sneezing.
The combination of HA and Tobramycin was more effective
in reducing hyposmia/anosmia and headache/facial pain than
HA alone, while no significant differences were found for other
ENT symptoms (Table 2).
Table 2
Changes in ENT symptoms.
Hyaluronate
(N = 13)
Hyaluronate +
tobramycin (N = 14)
P-value
Nasal obstruction
Improvement, n (%) 10 (77%) 9 (64%) 0.68
No change, n (%) 3 (23%) 5 (36%)
Worsening, n (%) 0 0
Mucopurulent rhinorrhea (subjective evaluation)
Improvement, n (%) 7 (54%) 9 (64%) 0.70
No change, n (%) 6 (46%) 5 (36%)
Worsening, n (%) 0 0
Hyposmia/anosmia
Improvement, n (%) 0 9 (64%) 0.001
No change, n (%) 12 (92%) 5 (36%)
Worsening, n (%) 1 (8%) 0
Snoring
Improvement, n (%) 2 (15%) 7 (50%) 0.103
No change, n (%) 10 (77%) 7 (50%)
Worsening, n (%) 1 (8) 0
Hedache/facial pain
Improvement, n (%) 1 (8%) 9 (64%) 0.004
No change, n (%) 12 (92%) 5 (36%)
Worsening, n (%) 0 0
Table 3
Changes in endoscopic assessment.
Hyaluronate
(N = 13)
Hyaluronate + tobramycin
(N = 14)
P-value
Status of the nasal mucosa
Improvement, n (%) 2 (15%) 11 (79%) 0.002
No change, n (%) 11 (85%) 3 (21%)
Worsening, n (%) 0 0
Mucopurulent secretion of osteomeatal complex
Reduced, n (%) 2 (15%) 11 (79%) 0.002
No change, n (%) 10 (77%) 3 (21%)
Increased, n (%) 1 (8%) 0
Hypertrophy of the right turbinate
Improvement, n (%) 2 (15%) 3 (21%) 1.00
No change, n (%) 11 (85%) 11 (79%)
Worsening, n (%) 0 0
Hypertrophy of the left turbinate
Improvement, n (%) 2 (15%) 4 (29%) 0.55
No change, n (%) 10 (77%) 8 (57%)
Worsening, n (%) 1 (8%) 2 (14%)
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combination of HA and Tobramycin was more effective than
HA alone in improving the status of the nasal mucosa and in
reducing nasal mucopurulent secretions. In contrast, no signifi-
cant differences between treatments were observed for hypertro-
phy of the right and left turbinate (Table 3).
More patients in the HA and tobramycin group had negative
nasal swab culture for S. aureus at the end of treatment
compared to patients receiving HA alone (57% vs. 31%),
although no statistical significance was detected (P = 0.25).
However, the analysis of bacterial load showed a quite similar
effect of the two treatments in reducing S. aureus in nasal swab
culture.
Of note, all the patients with positive nasal swab culture for
P. aeruginosa had a reduction of bacterial load after HA and
tobramycin treatment (Table 4). No patient showed acquisition
of P. aeruginosa after HA treatment.
To account for the different prevalence of P. aeruginosa
between the two treatment groups, we performed a further analysis
excluding the 4 patients with positive P. aeruginosa swab culture.
The greater efficacy of the formulation containing HA and
tobramycin was confirmed after removing the potential confound-
ing effect of P. aeruginosa in sinus. A greater proportion of
patients treated with HA and tobramycin experienced a reduction
of ENT symptom, compared to patients receiving HA alone
[Hyposmia/anosmia 6 (60%) vs. 0, P = 0.02; headache/facial pain
7 (70%) vs. 1 (8%), P = 0.006]. The status of the nasal mucosa
improved in 8 patients (80%) receiving HA and tobramycin and
in 2 (15%) treated with HA alone, P = 0.003. Similarly, the
proportion of patients who had a reduction of mucopurulent
secretions of the osteomeatal complex was greater in patients
receiving HA and Tobramycin [9 (90%) vs. 2 (15%), P = 0.001].3.1. Comparison of nasal and sputum culture at baseline
At screening visit, sputum was collected in 55 out of the 59
screened patients. Compared to nasal samples, P. aeruginosa
was detected in a higher proportion of sputum culture (20% vs.
9%), whereas the proportion of positive cultures for S. aureus
was similar (60% vs. 65%).
A significant association between infections of the upper and
lower airways was observed. The probability of finding a positive
sputum culture in patients with a positive nasal specimen was
7.88-fold higher for P. aeruginosa and 3.32-fold higher for
S. aureus compared with patients with a negative nasal culture
(Table 5).
4. Discussion
A major therapeutic purpose for patients with CF is to
prevent or delay chronic lung infections with CF-pathogenic
Gram-negative bacteria. CF-associated chronic rhinosinusitis
promote bacterial overgrowth that may represent a gateway
for bacterial colonization of the lower airways. This speculation
is supported by the findings of Mainz et al. [7], who found
the upper and lower airways of CF patients colonized by
genotypically identical strains of S. aureus and P. aeruginosa.
Common bacterial infections can develop in the context
of nasal congestion and obstruction and exacerbate the inflamma-
tory reaction. In this perspective, the treatment of the chronic
inflammatory processes that characterize rhinosinusitis may
prevent spread of infection and inflammation to the lower airways.
HA by inhalation is presently in clinical use in CF in
consideration of its water-retaining, re-epithelizing and anti-
inflammatory properties as well as of its capacity to restore ciliary
beat functions [11,12,15–18]. Moreover, intranasal sodium
hyaluronate was well tolerated in patients following functional
endoscopic sinus surgery for non CF-nasal polyposis [15].
Table 4
Nasal microbiology at the end of treatment.
Hyaluronate
(N = 13)
Hyaluronate +
tobramycin (N = 14)
P-value
Staphylococcus aureus
Nasal swab Negative, n (%) 4 (31%) 8 (57%) 0.25
Positive, n (%) 9 (69%) 6 (43%)
Bacterial load a
Reduced, n (%) 9 (69%) 11 (79%) 0.68
No change, n (%) 2 (15%) 3 (21%)
Increased, n (%) 2 (15%) 0
Pseudomonas aeruginosa
Nasal swab Negative, n (%) 13 (100%) 11 (79%) 0.22
Positive, n (%) 0 3 (21%)
Bacterial load a
Reduced, n (%) 0 4 (29%) 0.098
No change, n (%) 13 (100%) 9 (64%)
Increased, n (%) 0 1 (7%)
a To evaluate the change in bacterial load after treatment, we calculated the
differences between baseline and end of treatment of mean bacterial load of
right and left nostril.
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evaluate the potential benefits of topic treatment of HA with
tobramycin in CF-associated bacterial rhinosinusitis.
We hypothesized that when administered by the nasal spray
formulation, HA may be beneficial in alleviating symptoms by
covering the nasal mucosa with a softening and protective film,
thus providing a protective barrier and preventing dehydration. HA
may also facilitate the regeneration and hydration of the mucous
layer, thus improving its viscoelasticity and making it easier
to eject it adequately; by stimulating ciliary beating binding to
receptor for HA-mediated motility (RHAMM) [19], hyaluronan
would contribute to the removal from the nasal cavities of mucous
deposits and irritant agents, including pathogens. In addition, the
bacteriostatic and even the bactericidal effect of tobramycinmay be
strengthen by the three times a day administration as it was planned
in our study.
We enrolled patients with a positive nasal swab for respiratory
pathogens: in agreement with previous studies in children andTable 5
Association between lower and upper airways infections in screened patients
(N = 55 a).
Positive
sputum
cultures
Negative
sputum
cultures
Total OR (95% CI)
Pseudomonas aeruginosa
Positive nasal cultures 3 2 5 7.88 (1.13–54.93)
Negative nasal cultures 8 42 50
Total 11 44 55
Staphylococcus aureus
Positive nasal cultures 23 9 32 3.32 (1.07–10.27)
Negative nasal cultures 10 13 23
Total 33 22 55
a Sputum collection was not performed in 4 patients.adolescents, S. aureus was the predominant microorganism [20],
whereas P. aeruginosa has been isolated more frequently from
the upper airways of adult patients [8]. Endoscopic samples
targeting for the sinus ostia were obtained, which have been
shown to agree with maxillary sinus cultures [21]. An interesting
ancillary observation is that we found a higher probability of
lower airways infection by both S. aureus and P. aeruginosa in
patients with a positive sinus specimen. These findings seem to
support the results of the study by Mainz et al. [7] who found
identical genotypes in upper and lower airways, suggesting that
the upper airways play a role as a reservoir of S. aureus and
P. aeruginosa in CF.
The nasal spray formulation containing tobramycin and HA
was well tolerated and more effective than that containing HA
alone, not only in reducing ENT symptoms but also in restoring
eutrophism of the nasal mucosa, an effect that has never
been demonstrated previously with sodium HA alone. Equally
evident is the improvement of “mucopurulent nasal drip,”
which was observed with the combination of tobramycin-HA,
but not with HA solution alone: after 14 days of treatment, no
endoscopic traces of mucopurulent secretion were appreciated
in the nasal fossae of 86% of patients treated with tobramycin-
HA compared with only 15% of patients receiving HA
alone.
The therapeutic benefit derived from the association of the
two components may be explained by strengthening of the
eutrophic action of HA induced by the presence of tobramycin.
The nasal mucosa is colonized by both Gram-positive
and Gram-negative bacteria that produce hyaluronidase and
facilitate HA degradation, thus reducing its effectiveness.
Hyaluronidase cleaves the HA into lower molecular weight
fragments which are less effective; tobramycin, by lowering
the bacterial load, may delay the enzymatic degradation
of HA and consequently prolong its activity, thus playing a
crucial role when present in the formulation together with HA.
The well-known water-retaining activity of HA may also be
enhanced in terms of duration and entity by the bacteriostatic
action of tobramycin. Mucosal hydration and restoration of
the aqueous layer would promote mucociliary clearance and
facilitate the removal of contaminating particles, including
bacteria, thus reducing sinonasal inflammation and symptoms.
A significant endoscopic improvement was documented in
terms of increased mucosal trophism and reduced secretions.
Similarly, with regard to symptoms, although HA alone induced a
reduction of ENT symptoms, the addition of tobramycin resulted
in a further improvement as a result of the reduction of bacterial
load and consequently of secretions in the osteo-meatal complex
and in the nasal fossae. Treatment with tobramycin-HA spray
increased the thickness and trophism of the nasal epithelium as
compared with HA alone treatment. This better trophism of the
nasal mucosa may represent repair from epithelial damage caused
by chronic sinonasal inflammation.
In contrast, we could not demonstrate that the formulation
containing tobramycin and HA was more effective than HA alone
in the eradication of S. aureus from upper airways and in reducing
the bacterial load. The sample size was probably too small for this
outcome, and this issue should be further investigated.
460 M. Di Cicco et al. / Journal of Cystic Fibrosis 13 (2014) 455–460The present study suggests that the combination therapy
with HA plus tobramycin was more effective than HA alone in
the treatment of bacterial rhinosinusitis in CF. The percentage
of patients who experienced an improvement of ENT
symptoms, a better status of the nasal mucosa and a reduction
of mucopurulent secretion at the level of the osteomeatal
complex was higher in the group assigned to the combination
therapy than in the group that received HA alone.
To our knowledge, this is the first randomized double-blind
study that has assessed the tolerability and efficacy of a nasal
spray formulation containing HA and tobramycin compared
to a control formulation containing HA alone for nasal disease
in CF patients. However, a major limitation of our study is
that it is not placebo-controlled, and therefore the effects of
tobramycin in combination with HA could not be really
assessed since HA was administered to both groups.
It should be noted that the prevalence of P. aeruginosa
infections in our study population is lower than that commonly
reported in CF patients. Reducing spread of bacteria in these
patients would be a better clinical target. However, we could
demonstrate a significant clinical improvement also in patients
infected by S. aureus.
The efficacy and tolerability of the topical tobramycin-HA
treatment in sinonasal disease in CF patients observed in this study
should be confirmed in studies on a larger number of patients,
particularly those with positive cultures for P. aeruginosa and
with nasal polyps, in whom such treatment may prove to be even
more beneficial.
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